

Report from Industry Scientific Advisory Board

PPMI Annual Investigators Meeting
May 2-3, 2012

Thomas Comery



PARKINSON'S
PROGRESSION
MARKERS
INITIATIVE

Play a Part in Parkinson's Research



Industry Scientific Advisory Board (ISAB) Membership



Michelle Collins
Katherine Widnell



Mark Mintun

biogen idec

Bernard Ravina,
Chair-elect



Peggy Taylor



Ted Yednock



Igor Grachev



Marcel van der Brug



Alastair Reith



Johan Luthman
David Michelson



Thomas Comery,
Chair




Susanne Ostrowitzki
Paulo Fontoura



PARKINSON'S
PROGRESSION
MARKERS
INITIATIVE

Play a Part in Parkinson's Research

Industry Scientific Advisory Board Role



- Stakeholder role of the ISAB
 - Support Steering Committee
 - Input in Taskforces/Working groups
 - Participate in Annual Meeting and bi-monthly t-cons
 - Support efforts to identify additional partners
 - Suggest Ancillary Studies



PARKINSON'S
PROGRESSION
MARKERS
INITIATIVE

Play a Part in Parkinson's Research

Ancillary Studies Under Consideration by the ISAB

1. Develop a standard data compilation for use by ISAB members
2. Development of a quantitative Parkinson's disease progression model allowing:
 - simulation of potential trial designs (patient selection, trial size, duration)
 - improved understanding of the effect of drop-outs and placebo response
 - incorporation of biomarker-outcome relationships (neuropsychological, neuroimaging and biofluids)



PARKINSON'S
PROGRESSION
MARKERS
INITIATIVE




Play a Part in Parkinson's Research



Ancillary Studies Under Consideration by the ISAB

3. Addition of ASL-fMRI and spatial covariance analysis into PPMI

- Analysis of brain metabolic activity has identified networks associated with motor impairment, cognitive deficits and tremor in PD
- PPMI provides an opportunity to evaluate the robustness of these findings in a multi-center progression trial and correlate the findings with extensive motor and non-motor assessments



Tang et al., 2010

4. Characterization of α -synuclein variants in CSF, plasma and serum as candidate biomarkers for Parkinson's disease

- Establish a profile of α -synuclein variants in biofluids of older healthy volunteers and patients with Parkinson's disease




PARKINSON'S
PROGRESSION
MARKERS
INITIATIVE

Play a Part in Parkinson's Research

Ancillary Studies Under Consideration by the ISAB

5. Support the expansion of PPMI to include a cohort at risk for developing PD
 - Addition of an at risk population is key as designs and patient identification strategies for potential disease modifying therapies are being developed
 - Establish pre-motor biomarker signature



PARKINSON'S
PROGRESSION
MARKERS
INITIATIVE

Play a Part in Parkinson's Research

ISAB Next Steps

- Continue to support the PPMI goals and objectives through ISAB bi-monthly t-cons and participation in working groups
- Formulate and communicate ISAB member's needs as they arise
- Evaluate needs and gaps, recommend new ancillary studies to accelerate drug development in PD, biomarkers acceptance by regulators and develop new indications for approved products
- Support addition of new ISAB members to PPMI



PARKINSON'S
PROGRESSION
MARKERS
INITIATIVE

Play a Part in Parkinson's Research

